IRVINE, Calif., Sept. 05, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Rayonier Advanced Materials Inc. (“Rayonier” or the “Company”) (NYSE:RYAM). Investors who purchased or otherwise acquired shares between October 29, 2014 and August 19, 2015, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 16, 2017 lead plaintiff motion deadline.
If you purchased Rayonier shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Rayonier issued materially false and misleading statements, and/or failed to disclose adverse information. Specifically, despite the Company’s claims during the Class Period that in 2015 Rayonier “will be able to maintain or increase [its] share of volume at each of [its] top 10 customers,” since 2013, one of its top three customers, Eastman Chemical Company (“Eastman”), had been informing Rayonier of its competitors’ pricing and had requested that Rayonier respond to declines in market pricing. This led to a protracted dispute between Rayonier and Eastman over the “meet and release” provision of their agreement.
On August 18, 2015, the Company informed investors that the Company filed an action against Eastman regarding its “chemical cellulose specialty products contract with Eastman.” On August 19, 2015, Rayonier issued a press release further explaining the dispute with Eastman, stating that the language in the contract at issue involved the “meet or release” provisions of the agreement, which allowed Eastman to obtain “third party offers that meet the requirements of the Supply Agreement for similar cellulose specialties products, and would require [Rayonier] to either meet such price or release the volume, thereby allowing Eastman to purchase the volume from the third party.” The release also revealed that on August 12, 2017, Eastman filed an action against the Company regarding the same “meet or release” provisions in their contract. When this news was announced, shares of Rayonier fell in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 



